A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction

Table 3 Change and percentage change (in% by weight) in selected fatty acids and fatty acid ratios of interest between Day 0 and Day 28, by treatment, with statistical significance

Treatment	AA		EPA		DPA		DHA		EPA + DHA		AA:EPA		EPA + DPA + DHA		ω -3 FA		ω -6 FA		ω-3:ω-6 Ratio		ω-6:ω-3 Ratio
Treatment	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ	Δ	% Δ
rTG mean	-0.551	-3.27	1.469	151.1***	0.251	22.8**	1.177	44.6***	2.646	69.8***	-7.148	-56.7***	2.903	56.9***	2.807	47.5***	-2.626	-5.78**	0.080	57.6***	-2.507	-34.4***
rTG SD	1.770	14.60	0.691	102.69	0.312	28.01	0.628	36.49	1.150	44.37	4.271	13.62	1.218	34.63	1.244	28.671	3.889	8.970	0.033	30.403	1.342	11.366
EE mean	-0.316	-0.98	1.384	155.0***	0.189	17.0*	0.255	12.90	1.638	47.5***	-7.107	-54.3***	1.824	39.4***	1.826	33.9***	-1.572	-3.200	0.050	37.4***	-1.888	-24.7***
EE SD	2.207	19.54	0.847	123.65	0.273	24.74	0.656	31.80	1.365	49.05	4.745	18.13	1.521	41.46	1.497	34.923	4.153	9.537	0.029	28.093	1.413	13.871
PL mean	-0.260	-0.73	0.293	34.9*	0.150	14.5*	0.194	8.93	0.487	14.5*	-2.740	-17.2*	0.637	13.5***	0.523	10.200	-1.450	-2.720	0.017	13.2*	-0.782	-10.2*
PL SD	1.876	16.32	0.528	45.48	0.290	24.65	0.512	20.08	0.874	23.43	4.109	34.78	0.974	19.14	1.131	18.698	4.559	10.214	0.024	16.039	0.921	12.839
TG mean	-0.353	0.24	0.294	35.7**	0.014	4.37	0.447	18.9*	0.740	21.3**	-2.606	-17.9*	0.751	16.6***	0.752	14.2**	-0.703	-0.628	0.020	13.4*	-0.815	-11.4**
TG SD	2.206	20.22	0.493	43.34	0.301	21.60	0.596	27.34	0.866	25.65	4.249	34.61	1.118	23.20	1.161	20.229	4.509	10.030	0.020	12.827	0.791	11.331

∆ = change; %∆ = percent change; SD = Standard deviation; ***p-value - <0.0001 - <0.001; **p-value 0.001 – <0.01; ***p-value 0.01 – < 0.05.

ISSN: 1476-511X